Back

Efficacy of the novel thromboxane receptor antagonist NTP42 alone, or in combination with Sildenafil, in the sugen/hypoxia-induced model of pulmonary arterial hypertension

31 August 2019 (00:00 - 00:00)
Organised by:
Congress Presentation Part of: Poster Session 4 - Pulmonary arterial hypertension - Treatments Pharmacotherapy ESC Premium Access ESC Congress 2019

About the speaker

Photo
Professor Therese Kinsella

ATXA Therapeutics Limited, Dublin (Ireland)

10 More presentations in this session

Presentation thumbnail
Selexipag dosing and titration in the first 500 patients enrolled in SPHERE (SelexiPag: tHe UsErs dRug rEgistry)
Professor V. McLaughlin (Ann Arbor, US)
Abstract
Presentation thumbnail
Effects of inhaled nitrite in addition to sildenafil in thalassemia patients with pulmonary hypertension
Doctor T. Sasiprapha (Bangkok, TH)
Abstract Slides
Presentation thumbnail
Electroanatomical mapping of right atrium in patients with pulmonary hypertension
Doctor Z. Fingrova (Prague, CZ)
Abstract
Presentation thumbnail
Patient characteristics and treatment patterns in the multicentre, retrospective chart review of first-time Opsumit (macitentan) users in the United States (OrPHeUS)
Professor V. McLaughlin (Ann Arbor, US)
Abstract
Presentation thumbnail
Prognostic implications of early detection and treatment of left main coronary artery compression by a pulmonary artery among pulmonary arterial hypertension patients
Doctor J. Nuche (Madrid, ES)
Abstract

Access the full session

Session thumbnail
Poster Session 4 - Pulmonary arterial hypertension - Treatments

The Event

Event poster

ESC Congress 2019

31 August - 4 September 2019

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources